CA2968176C — Cgrp receptor antagonists
Assigned to Bristol Myers Squibb Co · Expires 2019-11-26 · 6y expired
What this patent protects
The disclosure generally relates to the novel compound (Intermediate 21), including pharmaceutically acceptable salts, which is a chemical intermediate for the manufacture of CGRP receptor antagonists. The disclosure also relates to processes for making CGRP receptor antagonists …
USPTO Abstract
The disclosure generally relates to the novel compound (Intermediate 21), including pharmaceutically acceptable salts, which is a chemical intermediate for the manufacture of CGRP receptor antagonists. The disclosure also relates to processes for making CGRP receptor antagonists using Intermediate 21. (See Formula 21)
Drugs covered by this patent
- Nurtec Odt (Rimegepant Sulfate) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.